CenterWatch reports that the fragmented US investigative site market is poised for acquisitions that may be driven by the most unlikely of sources: large European site management organizations (SMOs). The report, released in the January issue of The CenterWatch Monthly, provides an in-depth look at the infrastructure and strategies of the European companies likely to drive this wave of consolidation. The report signals opportunity and change for clinical research professionals in the US.
US investigative sites experienced an intense period of consolidation in the mid-to-late 1990s. At that time, venture-backed companies were on a buying spree to build large networks of physician investigators and standardize the management and conduct of industry-funded clinical trials. Since 2004, however, nearly all SMOs in the US. have either exited the clinical research market or diversified into other business areas. The investigative site landscape in the US. has become more fragmented, comprised of several thousand small research centers and two dozen medium-sized regional networks of practicing physicians participating in clinical trials.
CenterWatch now reports that a new type of SMO has been quietly growing in Europe, expanding into emerging regions including Latin America, India, and China during the late 2000s with ambitious plans to enter the US market in 2011. The complete report can be found in The CenterWatch Monthly, released today. Coverage includes detailed profiles of and interviews with the European SMOs driving this consolidation, and reaction from US clinical research professionals.
The CenterWatch Monthly is an in-depth newsletter covering the clinical trials industry, offering professionals at investigative sites, CROs and drug sponsors the latest news, trends, and grant opportunities. For subscription information visit the store at www.centerwatch.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.